Thanks to the predictive power of deep learning, large‐scale sequencing data of neoantigens and major histocompatibility complex (MHC) molecules can be used to test possible binding of truncated proteins of a tumor cell and the patient's human leukocyte antigen (HLA) system, enabling the discovery of treatment targets that would be both patient‐ and tumor‐specific. The gene discussed is HLA-C; the disease is neoplasm.